Document Detail


Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer.
MedLine Citation:
PMID:  8047832     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The clinical outcome and cost-effectiveness of episodic treatment of duodenal ulcer with omeprazole and ranitidine were evaluated over a 5-year period. The analysis was based on data from published clinical trials comparing healing rates obtained with omeprazole and with ranitidine, as well as on data from the literature on ulcer recurrence and other clinical events. Patients with an active duodenal ulcer were treated until healed or for a maximum of 24 weeks. Maintenance therapy was instituted in patients with ulcers that were very slow to heal and in patients with frequent relapses after cessation of treatment. Patients who experienced frequent relapses while receiving maintenance therapy, and those whose ulcer had not healed after 24 weeks of continuous treatment, were defined as candidates for surgery. A statistical model was set up and a random number generator used to generate a sequence of clinical events, month by month, over a 5-year period for each patient in a large cohort. Episodic treatment with omeprazole was shown to be more effective in avoiding maintenance treatment and surgery when compared with episodic treatment with ranitidine. Patients who received episodic treatment with omeprazole also spent more time in remission from disease. Using current Swedish cost data, it was found that episodic treatment with omeprazole was more cost-effective than episodic treatment with ranitidine.
Authors:
A Walan; S Eriksson
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Scandinavian journal of gastroenterology. Supplement     Volume:  201     ISSN:  0085-5928     ISO Abbreviation:  Scand. J. Gastroenterol. Suppl.     Publication Date:  1994  
Date Detail:
Created Date:  1994-09-01     Completed Date:  1994-09-01     Revised Date:  2008-02-13    
Medline Journal Info:
Nlm Unique ID:  0437034     Medline TA:  Scand J Gastroenterol Suppl     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  91-7     Citation Subset:  IM    
Affiliation:
Dept. of Medicine, Astra Hässle AB, Mölndal, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost-Benefit Analysis
Drug Costs / statistics & numerical data
Duodenal Ulcer / drug therapy*,  economics
Humans
Omeprazole / administration & dosage,  economics*
Probability
Prognosis
Ranitidine / administration & dosage,  economics*
Scandinavia
Treatment Outcome
Chemical
Reg. No./Substance:
66357-35-5/Ranitidine; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Economic evaluation of new medical technology.
Next Document:  Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease.